American Regent, Inc. clinical trials

Acquired by Daiichi Sankyo, Sep 28, 2005 · source ↗

The registry lists 53 studies whose lead sponsor is American Regent, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2025.

Studies

Recruiting first, then most recently updated. Showing 50 of 53. List all 53 → · All Daiichi Sankyo studies →

• Taxoprexin® Treatment for Advanced Eye MelanomaCompletedNCT00244816Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary TractTerminatedNCT00422877Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Taxoprexin Treatment for Advanced Skin MelanomaCompletedNCT00249262Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Taxoprexin Plus Carboplatin Treatment for Advanced Lung CancerCompletedNCT00243867Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant MelanomaTerminatedNCT00087776Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted before American Regent, Inc. became part of Daiichi Sankyo

• Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedNCT01290302Phase 1

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy AdultsCompletedNCT02478281Phase 1

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV IronCompletedNCT01950247Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving EpoetinCompletedNCT00239616Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on DialysisCompletedNCT00236964Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic ArteriolopathyWithdrawnNCT02527213Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Intravenous Iron Metabolism in Restless Legs SyndromeCompletedNCT00685815Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency AnemiaCompletedNCT00740246Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency AnemiaTerminatedNCT02826681Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese SafetyWithdrawnNCT05661682Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PNWithdrawnNCT05677126Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) PatientsCompletedNCT06690450Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical AssessmentsCompletedNCT00895232Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyCompletedNCT03037931Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency AnemiaWithdrawnNCT04968379Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDACompletedNCT02410213Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDACompletedNCT03523117Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044CompletedNCT04269707Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Efficacy of Iron Sucrose in ChildrenCompletedNCT00239642Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLSCompletedNCT02397057Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal DialysisCompletedNCT00236938Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®CompletedNCT02453334Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With AnemiaCompletedNCT00236977Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric BypassCompletedNCT02086968Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney DiseaseCompletedNCT02492672

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum PatientsCompletedNCT00548860Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease PatientsCompletedNCT00548691Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseCompletedNCT00317226Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)CompletedNCT01382901Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseCompletedNCT00317239Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum PatientsCompletedNCT00354484Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With FibromyalgiaCompletedNCT02409459Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency AnemiaCompletedNCT00703937Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric PatientsCompletedNCT00721188Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)CompletedNCT00982007Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine BleedingCompletedNCT00395993Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency AnemiaCompletedNCT00704028Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal FunctionCompletedNCT00981045Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency AnemiaCompletedNCT00704353Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin TherapyCompletedNCT00236951Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine BleedingCompletedNCT01307007Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in WomenCompletedNCT01290315Phase 2

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum AnemiaCompletedNCT00396292Phase 3

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)WithdrawnNCT01151592Phase 4

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo

• Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency AnemiaCompletedNCT01984554

  Sponsor listed in the registry: American Regent, Inc. · First submitted after American Regent, Inc. became part of Daiichi Sankyo